

Huldrych F Gunthard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2942086/publications.pdf>

Version: 2024-02-01

440
papers

29,247
citations

4960

84
h-index

7160

153
g-index

471
all docs

471
docs citations

471
times ranked

22426
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 306-316.	4.0	5
2	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2022, 74, 1468-1475.	5.8	3
3	Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals. <i>Aids</i> , 2022, 36, 205-214.	2.2	5
4	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	1.9	69
5	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 492-499.	3.0	7
6	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1592-1600.	4.0	4
7	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.	4.0	3
8	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
9	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	3.3	27
10	A highly virulent variant of HIV-1 circulating in the Netherlands. <i>Science</i> , 2022, 375, 540-545.	12.6	39
11	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 622-635.	9.1	135
12	Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load. <i>Virus Evolution</i> , 2022, 8, veac022.	4.9	1
13	Nonlinear mixed-effects models for HIV viral load trajectories before and after antiretroviral therapy interruption, incorporating left censoring. <i>Statistical Communications in Infectious Diseases</i> , 2022, 14, .	0.2	0
14	Impact of Latent Tuberculosis on Diabetes. <i>Journal of Infectious Diseases</i> , 2022, 225, 2229-2234.	4.0	3
15	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. <i>Viruses</i> , 2022, 14, 406.	3.3	1
16	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e585-e593.	5.8	26
17	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	2.1	0
18	Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	9

#	ARTICLE	IF	CITATIONS
19	The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. Journal of Infectious Diseases, 2022, 226, 1057-1068.	4.0	2
20	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. Viruses, 2022, 14, 784.	3.3	2
21	Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. Clinical Infectious Diseases, 2022, 75, 1723-1731.	5.8	14
22	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, , .	4.0	3
23	High Rates of Asymptomatic <i>Mycoplasma genitalium</i> Infections With High Proportion of Genotypic Resistance to First-Line Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich Primary HIV Infection Study. Open Forum Infectious Diseases, 2022, 9, .	0.9	7
24	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	8.2	26
25	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV, the, 2022, 9, e474-e485.	4.7	48
26	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. Haematologica, 2021, 106, 2233-2241.	3.5	4
27	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, e2194-e2202.	5.8	47
28	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. Clinical Infectious Diseases, 2021, 73, e2070-e2076.	5.8	7
29	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. Clinical Infectious Diseases, 2021, 73, e2134-e2141.	5.8	23
30	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. Clinical Infectious Diseases, 2021, 72, 2175-2183.	5.8	10
31	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 72, 1413-1421.	5.8	2
32	Assessing the potential impact of transmission during prolonged viral shedding on the effect of lockdown relaxation on COVID-19. PLoS Computational Biology, 2021, 17, e1008609.	3.2	6
33	Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	12.2	9
34	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. Nature Communications, 2021, 12, 1219.	12.8	2
35	The influence of human genetic variation on Epstein-Barr virus sequence diversity. Scientific Reports, 2021, 11, 4586.	3.3	8
36	Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab046.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Do we cause false positives? An experimental series on droplet or airborne SARS-CoV-2 contamination of sampling tubes during swab collection in a test center. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 51.	4.1	2
38	Assessing relative COVID-19 mortality: a Swiss population-based study. <i>BMJ Open</i> , 2021, 11, e042387.	1.9	9
39	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	3.9	66
40	A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells. <i>Viruses</i> , 2021, 13, 404.	3.3	3
41	HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection. <i>JCI Insight</i> , 2021, 6, .	5.0	7
42	High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children. <i>Microorganisms</i> , 2021, 9, 642.	3.6	41
43	Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	2
44	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	2.4	0
45	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063.	4.0	6
46	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. <i>ELife</i> , 2021, 10, .	6.0	3
47	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.	5.8	5
48	Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs. <i>Microorganisms</i> , 2021, 9, 1700.	3.6	11
49	Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C. <i>PLoS Computational Biology</i> , 2021, 17, e1008363.	3.2	2
50	Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 61-69.	2.1	6
51	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
52	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab032.	0.9	16
53	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 295.	2.4	11
54	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	5.8	16

#	ARTICLE	IF	CITATIONS
55	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. <i>Trials</i> , 2021, 22, 724.	1.6	9
56	Assessing relative COVID-19 mortality during the second wave: a prospective Swiss population-based study. <i>BMJ Open</i> , 2021, 11, e051164.	1.9	4
57	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021, 17, e1009529.	3.2	6
58	Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization. <i>Nature Communications</i> , 2021, 12, 6705.	12.8	9
59	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. <i>Nature Communications</i> , 2021, 12, 6703.	12.8	36
60	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. <i>Clinical Infectious Diseases</i> , 2020, 70, 297-303.	5.8	10
61	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013–2017, in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 637-644.	5.8	3
62	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. <i>International Journal of Cancer</i> , 2020, 147, 757-765.	5.1	5
63	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1651.	7.4	329
64	Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation. <i>Viruses</i> , 2020, 12, 1330.	3.3	9
65	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 517-524.	2.1	7
66	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 227-232.	2.1	13
67	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. <i>Viruses</i> , 2020, 12, 1241.	3.3	3
68	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	12.8	5
69	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	4.0	5
70	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	4.0	22
71	Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4506.	1.6	22
72	561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, S345-S346.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLA™HIV trial. PLoS Medicine, 2020, 17, e1003421.	8.4	23
74	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biology, 2020, 18, e3000963.	5.6	6
75	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	2.5	8
76	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Medicine, 2020, 17, e1003397.	8.4	7
77	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980â€“2018. Antiviral Therapy, 2020, 25, 43-54.	1.0	2
78	Title is missing!., 2020, 18, e3000963.		0
79	Title is missing!., 2020, 18, e3000963.		0
80	Title is missing!., 2020, 18, e3000963.		0
81	Title is missing!., 2020, 18, e3000963.		0
82	Title is missing!., 2020, 18, e3000963.		0
83	Title is missing!., 2020, 18, e3000963.		0
84	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
85	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
86	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
87	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
88	Title is missing!., 2020, 17, e1003421.		0
89	Title is missing!., 2020, 17, e1003421.		0
90	Title is missing!., 2020, 17, e1003421.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!., 2020, 17, e1003421.		0
92	Title is missing!., 2020, 17, e1003421.		0
93	Title is missing!., 2020, 17, e1003421.		0
94	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 68, 569-576.	5.8	30
95	Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society—USA Panel. Clinical Infectious Diseases, 2019, 68, 177-187.	5.8	156
96	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.9	28
97	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	12.8	112
98	Mortality from suicide among people living with HIV and the general Swiss population: 1988–2017. Journal of the International AIDS Society, 2019, 22, e25339.	3.0	24
99	Population pharmacokinetics of dolutegravir: influence of drug–drug interactions in a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 2690-2697.	3.0	23
100	Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit: Evaluation of the First 105 Cases. Genes, 2019, 10, 661.	2.4	41
101	Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. Journal of Experimental Medicine, 2019, 216, 2071-2090.	8.5	22
102	The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. Antiviral Therapy, 2019, 24, 343-353.	1.0	4
103	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	13.7	627
104	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	4.0	6
105	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	4.0	27
106	Clusters of Sexual Behavior in Human Immunodeficiency Virus–positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. Clinical Infectious Diseases, 2019, 70, 416-424.	5.8	9
107	Reply to Ambrosioni et al. Clinical Infectious Diseases, 2019, 68, 1977-1978.	5.8	0
108	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. Journal of Infectious Diseases, 2019, 220, 91-99.	4.0	24

#	ARTICLE	IF	CITATIONS
109	IL-4 polymorphism influences susceptibility to <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive patients. <i>Aids</i> , 2019, 33, 1719-1727.	2.2	9
110	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 314-320.	2.1	6
111	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 508-515.	2.1	0
112	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 1489-1497.	5.8	19
113	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 468-472.	3.0	9
114	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2019, 68, 561-568.	5.8	13
115	2019 update of the drug resistance mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2019, 27, 111-121.	0.1	127
116	Antibacterial Effects of Antiretrovirals, Potential Implications for Microbiome Studies in HIV. <i>Antiviral Therapy</i> , 2018, 23, 91-94.	1.0	28
117	High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 735-742.	5.8	37
118	MRI and PET-CT Failed to Differentiate Between Hepatic Malignancy and Brucelloma. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy052.	0.9	1
119	Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1917-1929.	3.0	16
120	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. <i>Journal of Immunological Methods</i> , 2018, 454, 48-58.	1.4	17
121	No Effect of Pegylated Interferon- α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018, 217, 1883-1888.	4.0	10
122	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , 2018, 32, 327-335.	2.2	13
123	On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 10-18.	2.0	20
124	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018, 4, vey024.	4.9	17
125	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. <i>Aids</i> , 2018, 32, 2759-2765.	2.2	6
126	Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2154.	7.4	0

#	ARTICLE	IF	CITATIONS
127	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. <i>Virus Evolution</i> , 2018, 4, vey007.	4.9	64
128	Can Directionality of HIV Transmission be Predicted by Next-Generation Sequencing Data?. <i>Journal of Infectious Diseases</i> , 2018, 220, 1393-1395.	4.0	3
129	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018, 35, 27-37.	8.9	37
130	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	27.8	47
131	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy078.	0.9	8
132	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	8.5	29
133	HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 566-573.	2.1	14
134	OMIP-047: High-Dimensional phenotypic characterization of B cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 592-596.	1.5	18
135	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 379.	7.4	486
136	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 486.	4.8	91
137	Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector. <i>Scientific Reports</i> , 2018, 8, 10204.	3.3	8
138	Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. <i>PLoS Pathogens</i> , 2018, 14, e1006895.	4.7	53
139	In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells. <i>Molecular and Cellular Proteomics</i> , 2017, 16, S108-S123.	3.8	18
140	Mining for pairs: shared clinic visit dates identify steady <sc>HIV</sc>-positive partnerships. <i>HIV Medicine</i> , 2017, 18, 667-676.	2.2	2
141	Prescription of Postexposure Prophylaxis for HIV-1 in the Emergency Room: Correct Transmission Risk Assessment Remains Challenging. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 359-366.	2.1	9
142	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	5.8	23
143	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , 2017, 18, 225-235.	6.1	28
144	Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e114-e117.	2.1	5

#	ARTICLE	IF	CITATIONS
145	Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. <i>Medicine (United States)</i> , 2017, 96, e5849.	1.0	36
146	Human papillomavirus antibody response following HAART initiation among MSM. <i>Aids</i> , 2017, 31, 561-569.	2.2	11
147	Adverse events of raltegravir and dolutegravir. <i>Aids</i> , 2017, 31, 1853-1858.	2.2	91
148	Reply to correspondence "Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic process" by Gonzalez et al., <i>Retrovirology</i> 2017. <i>Retrovirology</i> , 2017, 14, 14.	2.0	3
149	Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup. <i>Retrovirology</i> , 2017, 14, 33.	2.0	16
150	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	3.7	101
151	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017, 6, .	6.0	16
152	Life expectancy in HIV-positive persons in Switzerland. <i>Aids</i> , 2017, 31, 427-436.	2.2	193
153	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. <i>PLoS Biology</i> , 2017, 15, e2001855.	5.6	38
154	Phylodynamics on local sexual contact networks. <i>PLoS Computational Biology</i> , 2017, 13, e1005448.	3.2	16
155	Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. <i>PLoS Pathogens</i> , 2017, 13, e1006255.	4.7	27
156	Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. <i>PLoS Pathogens</i> , 2017, 13, e1006313.	4.7	23
157	Assessment of Overlap of Phylogenetic Transmission Clusters and Communities in Simple Sexual Contact Networks: Applications to HIV-1. <i>PLoS ONE</i> , 2016, 11, e0148459.	2.5	28
158	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 191.	7.4	533
159	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. <i>Scientific Reports</i> , 2016, 6, 27580.	3.3	15
160	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016, 18, 814-822.	2.4	36
161	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 399-402.	4.0	47
162	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	30.7	133

#	ARTICLE	IF	CITATIONS
163	Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4+ T cells. <i>Scientific Reports</i> , 2016, 6, 24157.	3.3	21
164	Large-scale inference of conjunctive Bayesian networks. <i>Bioinformatics</i> , 2016, 32, i727-i735.	4.1	21
165	HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance. <i>Journal of Infectious Diseases</i> , 2016, 214, 1289-1291.	4.0	1
166	Identification of Siglec-1 null individuals infected with HIV-1. <i>Nature Communications</i> , 2016, 7, 12412.	12.8	38
167	A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. <i>Scientific Reports</i> , 2016, 6, 32251.	3.3	17
168	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. <i>Retrovirology</i> , 2016, 13, 62.	2.0	45
169	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016, 95, e5094.	1.0	22
170	Immune recovery in HIV-infected patients after <i>Candida</i> esophagitis is impaired despite long-term antiretroviral therapy. <i>Aids</i> , 2016, 30, 1923-1933.	2.2	6
171	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. <i>Journal of Infectious Diseases</i> , 2016, 214, 599-606.	4.0	34
172	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
173	A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations. <i>Journal of Molecular Biology</i> , 2016, 428, 238-250.	4.2	25
174	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	3.0	4
175	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1310-1317.	5.8	52
176	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 115-122.	5.8	60
177	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. <i>Clinical Microbiology and Infection</i> , 2016, 22, 191-200.	6.0	27
178	2017 Update of the Drug Resistance Mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2016, 24, 132-133.	0.1	132
179	Virological Outcome and Management of Persistent Low-Level Viraemia in HIV-1-Infected Patients: 11 Years of the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2015, 20, 165-175.	1.0	41
180	Molecular Analyses Define VÎ±7.2-JÎ±33+ MAIT Cell Depletion in HIV Infection. <i>Medicine (United States)</i> , 2015, 94, e1134.	1.0	23

#	ARTICLE	IF	CITATIONS
181	Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution. <i>Methods in Ecology and Evolution</i> , 2015, 6, 67-82.	5.2	22
182	Gut commensal microbes do not represent a dominant antigenic source for continuous CD4 ⁺ T cell activation during HIV-1 infection. <i>European Journal of Immunology</i> , 2015, 45, 3107-3113.	2.9	1
183	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.	2.2	5
184	The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. <i>Aids</i> , 2015, 29, 1803-1810.	2.2	8
185	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. <i>Aids</i> , 2015, 29, 2195-2200.	2.2	58
186	Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection. <i>Clinical Infectious Diseases</i> , 2015, 61, 1013-1021.	5.8	67
187	A Framework for Inferring Fitness Landscapes of Patient-Derived Viruses Using Quasispecies Theory. <i>Genetics</i> , 2015, 199, 191-203.	2.9	28
188	Increases in Condomless Sex in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv077-ofv077.	0.9	35
189	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. <i>Drug Metabolism and Disposition</i> , 2015, 44, 151-161.	3.3	27
190	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. <i>BMC Infectious Diseases</i> , 2015, 15, 382.	2.9	29
191	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 930-940.	3.0	102
192	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.	4.0	61
193	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , 2015, 16, 297-306.	2.2	9
194	Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds. <i>PLoS Pathogens</i> , 2015, 11, e1004722.	4.7	68
195	Estimating the dynamics and dependencies of accumulating mutations with applications to HIV drug resistance. <i>Biostatistics</i> , 2015, 16, 713-726.	1.5	3
196	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015, 212, 578-584.	4.0	20
197	Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. <i>Gut</i> , 2015, 64, 813-819.	12.1	65
198	Cluster of Leptospirosis Acquired Through River Surfing in Switzerland. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv102.	0.9	15

#	ARTICLE	IF	CITATIONS
199	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv257.	3.0	6
200	Editorial Commentary: The Irreversibility of HIV Drug Resistance. <i>Clinical Infectious Diseases</i> , 2015, 61, 837-839.	5.8	19
201	The Orientation of HIV-1 gp120 Binding to the CD4 Receptor Differentially Modulates CD4+ T Cell Activation. <i>Journal of Immunology</i> , 2015, 194, 637-649.	0.8	9
202	Subacute, tetracycline-responsive, granulomatous osteomyelitis in an adult man, consistent with Q fever infection. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212426.	0.5	3
203	HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages. <i>PLoS ONE</i> , 2015, 10, e0132127.	2.5	15
204	2015 Update of the Drug Resistance Mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2015, 23, 132-41.	0.1	103
205	Changes in Biomarkers of Liver Disease during Successful Combination Antiretroviral Therapy in HIV/HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2014, 19, 149-159.	1.0	11
206	Role of MicroRNA Modulation in the Interferon- α /Ribavirin Suppression of HIV-1 In Vivo. <i>PLoS ONE</i> , 2014, 9, e109220.	2.5	7
207	High-Throughput Sequencing of Human Immunoglobulin Variable Regions with Subtype Identification. <i>PLoS ONE</i> , 2014, 9, e111726.	2.5	27
208	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. <i>PLoS ONE</i> , 2014, 9, e114111.	2.5	17
209	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. <i>Retrovirology</i> , 2014, 11, 75.	2.0	16
210	Disentangling Human Tolerance and Resistance Against HIV. <i>PLoS Biology</i> , 2014, 12, e1001951.	5.6	53
211	Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. <i>Nucleic Acids Research</i> , 2014, 42, e115-e115.	14.5	126
212	Quantifying the Turnover of Transcriptional Subclasses of HIV-1-Infected Cells. <i>PLoS Computational Biology</i> , 2014, 10, e1003871.	3.2	19
213	Using an Epidemiological Model for Phylogenetic Inference Reveals Density Dependence in HIV Transmission. <i>Molecular Biology and Evolution</i> , 2014, 31, 6-17.	8.9	55
214	New Onset of Kaposi Sarcoma in a Human Immunodeficiency Virus-1-Infected Homosexual Man, Despite Early Antiretroviral Treatment, Sustained Viral Suppression, and Immune Restoration. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu005.	0.9	9
215	CD8+ T Cells Are Activated in an Antigen-Independent Manner in HIV-Infected Individuals. <i>Journal of Immunology</i> , 2014, 192, 1732-1744.	0.8	52
216	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. <i>Aids</i> , 2014, 28, 2231-2239.	2.2	20

#	ARTICLE	IF	CITATIONS
217	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2014, 312, 410.	7.4	428
218	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2014, 58, 285-294.	5.8	75
219	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. International Journal of Epidemiology, 2014, 43, 887-896.	1.9	36
220	The IFNL3/4 \uparrow G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. Aids, 2014, 28, 1885-1889.	2.2	37
221	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>In Vivo</i> . Journal of Virology, 2014, 88, 763-767.	3.4	29
222	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 2014, 210, 1555-1561.	4.0	16
223	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. American Journal of Epidemiology, 2014, 179, 1514-1525.	3.4	25
224	Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus. Clinical Infectious Diseases, 2014, 59, 1386-1393.	5.8	9
225	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. Retrovirology, 2014, 11, 75.	2.0	14
226	2014 Update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2014, 22, 642-50.	0.1	173
227	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. Clinical Infectious Diseases, 2013, 57, 112-121.	5.8	56
228	Expansion of interferon- γ -secreting HIV-specific T cells during successful antiretroviral therapy. HIV Medicine, 2013, 14, 241-246.	2.2	5
229	Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. Aids, 2013, 27, 203-210.	2.2	23
230	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. PLoS Computational Biology, 2013, 9, e1003203.	3.2	19
231	24 Hours in the Life of HIV-1 in a T Cell Line. PLoS Pathogens, 2013, 9, e1003161.	4.7	134
232	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	4.0	7
233	How effectively can HIV phylogenies be used to measure heritability?. Evolution, Medicine and Public Health, 2013, 2013, 209-224.	2.5	21
234	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1102-1112.	4.0	35

#	ARTICLE	IF	CITATIONS
235	Probing of viral diversity by global haplotype prediction. , 2013, , .		0
236	Early and nonreversible decrease of CD161 ⁺⁺ /MAIT cells in HIV infection. Blood, 2013, 121, 951-961.	1.4	307
237	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 28-35.	2.1	86
238	Response to Calcagno Comment on “Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid” Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, e14-e15.	2.1	1
239	Efavirenz intoxication due to a new CYP2B6 constellation. Antiviral Therapy, 2013, 18, 735-738.	1.0	6
240	Simple Estimation of Incident HIV Infection Rates in Notification Cohorts Based on Window Periods of Algorithms for Evaluation of Line-Immunoassay Result Patterns. PLoS ONE, 2013, 8, e71662.	2.5	7
241	Next-Generation Sequencing of HIV-1 RNA Genomes: Determination of Error Rates and Minimizing Artificial Recombination. PLoS ONE, 2013, 8, e74249.	2.5	55
242	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 2013, 23, 9-18.	1.5	25
243	Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study. PLoS ONE, 2013, 8, e77691.	2.5	49
244	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. ELife, 2013, 2, e01123.	6.0	126
245	Update of the drug resistance mutations in HIV-1: March 2013. Topics in Antiviral Medicine, 2013, 21, 6-14.	0.1	197
246	Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 2012, 29, 347-357.	8.9	206
247	Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies. PLoS Pathogens, 2012, 8, e1002634.	4.7	189
248	Inferring Epidemic Contact Structure from Phylogenetic Trees. PLoS Computational Biology, 2012, 8, e1002413.	3.2	85
249	Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. PLoS Pathogens, 2012, 8, e1002529.	4.7	306
250	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 2012, 56, 2959-2966.	3.2	39
251	Role of retroviral restriction factors in the interferon- γ -mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3035-3040.	7.1	129
252	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-naïve Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.	5.8	32

#	ARTICLE	IF	CITATIONS
253	Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. <i>Clinical Infectious Diseases</i> , 2012, 55, 1408-1416.	5.8	225
254	Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. <i>Aids</i> , 2012, 26, 193-205.	2.2	78
255	Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. <i>Frontiers in Microbiology</i> , 2012, 3, 329.	3.5	204
256	Polymorphic Mutations Associated With the Emergence of the Multinucleoside/Tide Resistance Mutations 69 Insertion and Q151M. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 105-112.	2.1	9
257	Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. <i>BMC Infectious Diseases</i> , 2012, 12, 88.	2.9	12
258	Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. <i>Retrovirology</i> , 2012, 9, 27.	2.0	39
259	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. <i>PLoS ONE</i> , 2012, 7, e37983.	2.5	15
260	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. <i>PLoS ONE</i> , 2012, 7, e50307.	2.5	16
261	A rare but severe pulmonary side effect of cetuximab in two patients. <i>BMJ Case Reports</i> , 2012, 2012, bcr0320125973-bcr0320125973.	0.5	17
262	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 387-402.	7.4	1,239
263	<scp>HLA</scp>â€<scp>Bw4</scp> identifies a population of <scp>HIV</scp>â€infectd patients with an increased capacity to control viral replication after structured treatment interruption. <i>HIV Medicine</i> , 2012, 13, 589-595.	2.2	2
264	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. <i>PLoS ONE</i> , 2012, 7, e29186.	2.5	21
265	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	9.1	345
266	Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1â€infectd Eritrean Immigrant. <i>Emerging Infectious Diseases</i> , 2011, 17, 1966-1968.	4.3	9
267	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011, 6, e27903.	2.5	21
268	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 24-31.	2.1	23
269	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 253-260.	2.1	19
270	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. <i>Antiviral Therapy</i> , 2011, 16, 535-545.	1.0	77

#	ARTICLE	IF	CITATIONS
271	Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2011, 12, 299-307.	2.2	13
272	Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. <i>Journal of Translational Medicine</i> , 2011, 9, 14.	4.4	8
273	A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression. <i>Retrovirology</i> , 2011, 8, .	2.0	1
274	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011, 53, 1446-1454.	7.3	56
275	MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. <i>Journal of Experimental Medicine</i> , 2011, 208, 439-454.	8.5	95
276	Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. <i>Journal of Experimental Medicine</i> , 2011, 208, 1419-1433.	8.5	92
277	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipodystrophy. <i>Journal of Infectious Diseases</i> , 2011, 203, 620-624.	4.0	11
278	Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 791-797.	4.0	9
279	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.	4.0	74
280	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , 2011, 60, 1506-1519.	12.1	60
281	Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting. <i>PLoS Pathogens</i> , 2011, 7, e1002321.	4.7	37
282	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.	5.8	53
283	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1271-1279.	5.8	84
284	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.	4.0	89
285	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	5.8	127
286	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. <i>Journal of Clinical Investigation</i> , 2011, 121, 2391-2400.	8.2	168
287	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	2.5	46
288	2011 update of the drug resistance mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2011, 19, 156-64.	0.1	207

#	ARTICLE	IF	CITATIONS
289	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
290	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. <i>Aids</i> , 2010, 24, 1177-1183.	2.2	62
291	Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. <i>Aids</i> , 2010, 24, 2451-2460.	2.2	210
292	Pulmonary Toxoplasmosis, a Rare but Severe Manifestation of a Common Opportunistic Infection in Late HIV Presenters: Report of Two Cases. <i>Infection</i> , 2010, 38, 141-144.	4.7	14
293	Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case. <i>Infection</i> , 2010, 38, 423-426.	4.7	20
294	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. <i>Journal of Virological Methods</i> , 2010, 165, 151-160.	2.1	33
295	HIV-1 replication activates CD4 ⁺ T cells with specificities for persistent herpes viruses. <i>EMBO Molecular Medicine</i> , 2010, 2, 231-244.	6.9	13
296	Association between specific HIV-1 Env traits and virologic control in vivo. <i>Infection, Genetics and Evolution</i> , 2010, 10, 365-372.	2.3	2
297	Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 197-203.	2.1	91
298	Aortic homograft endocarditis caused by <i>Cardiobacterium hominis</i> and complicated by agranulocytosis due to ceftriaxone. <i>BMJ Case Reports</i> , 2010, 2010, bcr0420102894-bcr0420102894.	0.5	6
299	Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. <i>Aids</i> , 2010, 24, 2347-2354.	2.2	101
300	Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression. <i>PLoS ONE</i> , 2010, 5, e11079.	2.5	78
301	Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection. <i>PLoS ONE</i> , 2010, 5, e13310.	2.5	84
302	Failure to Detect Xenotropic Murine Leukemia Virus-Related Virus in Blood of Individuals at High Risk of Blood-Borne Viral Infections. <i>Journal of Infectious Diseases</i> , 2010, 202, 1482-1485.	4.0	40
303	Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase. <i>Journal of Infectious Diseases</i> , 2010, 201, 1054-1062.	4.0	27
304	Efficient Suppression of Minority Drug-Resistant HIV Type 1 (HIV-1) Variants Present at Primary HIV-1 Infection by Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 1063-1071.	4.0	51
305	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010, 59, 1252-1258.	12.1	46
306	Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	4.0	172

#	ARTICLE	IF	CITATIONS
307	HIV-1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 51, 620-628.	5.8	26
308	2010 Guidelines for Antiretroviral Treatment of HIV From the International AIDS Society's "USA Panel" Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1897.	7.4	3
309	Differences in HIV Burden and Immune Activation within the Gut of HIV-Positive Patients Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 202, 1553-1561.	4.0	262
310	Cohort Profile: The Swiss HIV Cohort Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1179-1189.	1.9	322
311	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	4.7	108
312	Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals. <i>PLoS Pathogens</i> , 2010, 6, e1000781.	4.7	158
313	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 321.	7.4	732
314	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 464-471.	2.1	17
315	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. <i>Gastroenterology</i> , 2010, 138, 1338-1345.e7.	1.3	1,056
316	Outcomes of Patients on Dual-Boosted PI Regimens: Experience of the Swiss HIV Cohort Study. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1239-1246.	1.1	4
317	Update of the drug resistance mutations in HIV-1: December 2010. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2010, 18, 156-63.	2.9	98
318	Effects of HIV type-1 immune selection on susceptibility to integrase inhibitor resistance. <i>Antiviral Therapy</i> , 2009, 14, 953-964.	1.0	4
319	Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naïve and -Adherent Patients. <i>Clinical Infectious Diseases</i> , 2009, 48, 239-247.	5.8	188
320	The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. <i>Aids</i> , 2009, 23, 1415-1423.	2.2	96
321	Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.	3.5	377
322	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	5.8	43
323	HIV-1 Superinfection in an HIV-2-Infected Woman with Subsequent Control of HIV-1 Plasma Viremia. <i>Clinical Infectious Diseases</i> , 2009, 48, e117-e120.	5.8	27
324	Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. <i>Virology</i> , 2009, 387, 98-108.	2.4	62

#	ARTICLE	IF	CITATIONS
325	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. <i>Hepatology</i> , 2009, 49, 1069-1082.	7.3	131
326	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009, 50, 1017-1029.	7.3	60
327	Spontaneous Splenic Rupture as Manifestation of the Immune Reconstitution Inflammatory Syndrome in an HIV Type 1 Infected Patient with Tuberculosis. <i>Infection</i> , 2009, 37, 163-165.	4.7	8
328	Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). <i>HIV Medicine</i> , 2009, 10, 647-656.	2.2	20
329	A LCâ€‘tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1057-1069.	2.3	101
330	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 409-417.	9.1	216
331	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 300-309.	1.5	133
332	HIV sensitivity to neutralization is determined by target and virus producer cell properties. <i>Aids</i> , 2009, 23, 1659-1667.	2.2	47
333	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009, 14, 771-779.	1.0	9
334	African descent is associated with slower CD4 cell count decline in treatment-naïve patients of the Swiss HIV Cohort Study. <i>Aids</i> , 2009, 23, 1269-1276.	2.2	28
335	Divergent effects of cell environment on HIV entry inhibitor activity. <i>Aids</i> , 2009, 23, 1319-1327.	2.2	28
336	Update of the drug resistance mutations in HIV-1: December 2009. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2009, 17, 138-45.	2.9	86
337	Reliability formula & limit law of the failure time of k -out-of- n :F system. <i>Top</i> , 2008, 16, 62-72.	1.6	81
338	Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. <i>Retrovirology</i> , 2008, 5, 107.	2.0	44
339	Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Societyâ€‘USA Panel. <i>Clinical Infectious Diseases</i> , 2008, 47, 266-285.	5.8	428
340	Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked. <i>Journal of Virology</i> , 2008, 82, 3834-3842.	3.4	24
341	The HCP5 Single Nucleotide Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity Reaction to Abacavir. <i>Journal of Infectious Diseases</i> , 2008, 198, 864-867.	4.0	90
342	Acute Cytomegalovirus Colitis Presenting during Primary HIV Infection: an Unusual Case of an Immune Reconstitution Inflammatory Syndrom. <i>Clinical Infectious Diseases</i> , 2008, 46, e38-e40.	5.8	21

#	ARTICLE	IF	CITATIONS
343	In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers. <i>Journal of Virology</i> , 2008, 82, 1591-1599.	3.4	50
344	HIV rebounds from latently infected cells, rather than from continuing low-level replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16725-16730.	7.1	273
345	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	5.8	35
346	Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 1921-1925.	5.8	28
347	Dynamics of Total, Linear Nonintegrated, and Integrated HIV-1 DNA In Vivo and In Vitro. <i>Journal of Infectious Diseases</i> , 2008, 197, 411-419.	4.0	149
348	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008, 22, 2481-2492.	2.2	18
349	Antibody responses in primary HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 45-51.	3.8	18
350	Update of the Drug Resistance Mutations in HIV-1. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2008, 16, 138-45.	2.9	79
351	In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10. <i>Journal of Virology</i> , 2007, 81, 8793-8808.	3.4	85
352	Effective T-Cell Responses Select Human Immunodeficiency Virus Mutants and Slow Disease Progression. <i>Journal of Virology</i> , 2007, 81, 6742-6751.	3.4	109
353	HIV Patients Developing Primary CNS Lymphoma Lack EBV-Specific CD4+ T Cell Function Irrespective of Absolute CD4+ T Cell Counts. <i>PLoS Medicine</i> , 2007, 4, e96.	8.4	81
354	Positive In Vivo Selection of the HIV-1 Envelope Protein gp120 Occurs at Surface-Exposed Regions. <i>Journal of Infectious Diseases</i> , 2007, 196, 313-320.	4.0	36
355	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , 2007, 21, 2223-2229.	2.2	117
356	Precise Identification of a Human Immunodeficiency Virus Type 1 Antigen Processing Mutant. <i>Journal of Virology</i> , 2007, 81, 2031-2038.	3.4	30
357	Impact of HIV-1 Reverse Transcriptase Polymorphism F214L on Virological Response to Thymidine Analogue-Based Regimens in Antiretroviral Therapy (ART)-Naïve and ART-Experienced Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 1180-1190.	4.0	12
358	Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment_{A Comparison of Different Regimen Types}. <i>Archives of Internal Medicine</i> , 2007, 167, 1782.	3.8	116
359	Productive Human Immunodeficiency Virus Type 1 Infection in Peripheral Blood Predominantly Takes Place in CD4/CD8 Double-Negative T Lymphocytes. <i>Journal of Virology</i> , 2007, 81, 9693-9706.	3.4	72
360	Persistence of Lamivudine-Sensitive HIV-1 Quasispecies in the Presence of Lamivudine In Vitro and In Vivo. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 377-385.	2.1	12

#	ARTICLE	IF	CITATIONS
361	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007, 21, 2201-2207.	2.2	7
362	Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 557-566.	4.7	240
363	Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. <i>PLoS ONE</i> , 2007, 2, e173.	2.5	31
364	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006, 20, 889-894.	2.2	52
365	Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. <i>Aids</i> , 2006, 20, 35-40.	2.2	57
366	Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART. <i>Journal of Medical Virology</i> , 2006, 78, 1003-1010.	5.0	40
367	HIV replication elicits little cytopathic effects in vivo: Analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. <i>Journal of Medical Virology</i> , 2006, 78, 1141-1146.	5.0	12
368	Genetic attributes of cerebrospinal fluid-derived HIV-1 env. <i>Brain</i> , 2006, 129, 1872-1883.	7.6	94
369	Equal Amounts of Intracellular and Virion-Enclosed Hepatitis C Virus RNA Are Associated with Peripheral-Blood Mononuclear Cells In Vivo. <i>Journal of Infectious Diseases</i> , 2006, 194, 1713-1723.	4.0	25
370	Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection. <i>PLoS Medicine</i> , 2006, 3, e441.	8.4	92
371	Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1773-1779.	3.2	63
372	A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-14.	1.0	4
373	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-314.	1.0	10
374	Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. <i>Nature Medicine</i> , 2005, 11, 615-622.	30.7	468
375	Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions. <i>Journal of Virology</i> , 2005, 79, 9026-9037.	3.4	40
376	Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy. <i>Journal of Virology</i> , 2005, 79, 1772-1788.	3.4	136
377	Risk Factors for and Outcome of Hyperlactatemia in HIV-Infected Persons: Is There a Need for Routine Lactate Monitoring?. <i>Clinical Infectious Diseases</i> , 2005, 41, 721-728.	5.8	36
378	Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. <i>Journal of Virology</i> , 2005, 79, 8454-8469.	3.4	76

#	ARTICLE	IF	CITATIONS
379	Effect of Treatment, during Primary Infection, on Establishment and Clearance of Cellular Reservoirs of HIV-1. <i>Journal of Infectious Diseases</i> , 2005, 191, 1410-1418.	4.0	294
380	Efavirenz Intoxication Due to Slow Hepatic Metabolism. <i>Clinical Infectious Diseases</i> , 2005, 40, e22-e23.	5.8	73
381	Gilbert Syndrome and the Development of Antiretroviral Therapyâ€‘Associated Hyperbilirubinemia. <i>Journal of Infectious Diseases</i> , 2005, 192, 1381-1386.	4.0	182
382	Successful Treatment with Miltefosine of Disseminated Cutaneous Leishmaniasis in a Severely Immunocompromised Patient Infected with HIV-1. <i>Clinical Infectious Diseases</i> , 2005, 40, e120-e124.	5.8	49
383	Biphasic decline of CD4 cell count during scheduled treatment interruptions. <i>Aids</i> , 2005, 19, 439-441.	2.2	22
384	HIV-1 p24 May Persist During Long-Term Highly Active Antiretroviral Therapy, Increases Little During Short Treatment Breaks, and Its Rebound After Treatment Stop Correlates With CD4+ T Cell Loss. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 250-256.	2.1	23
385	Cellular Viral Rebound after Cessation of Potent Antiretroviral Therapy Predicted by Levels of Multiply Spliced HIVâ€‘1 RNA Encodingnef. <i>Journal of Infectious Diseases</i> , 2004, 190, 1979-1988.	4.0	56
386	Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 12266-12270.	7.1	76
387	Entry and Transcription as Key Determinants of Differences in CD4 T-Cell Permissiveness to Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2004, 78, 10747-10754.	3.4	46
388	Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. <i>Aids</i> , 2004, 18, 1951-1953.	2.2	73
389	Attenuated and Nonproductive Viral Transcription in the Lymphatic Tissue of HIVâ€‘1â€‘Infected Patients Receiving Potent Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2004, 189, 273-285.	4.0	37
390	Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. <i>Virology</i> , 2004, 326, 113-129.	2.4	76
391	Antiretroviral Treatment and Osteonecrosis in Patients of the Swiss HIV Cohort Study: A Nested Case-Control Study. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 909-915.	1.1	28
392	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. <i>Blood</i> , 2004, 104, 1784-1792.	1.4	46
393	Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial. <i>Antiviral Therapy</i> , 2004, 9, 85-95.	1.0	61
394	Aortic Homograft Endocarditis Caused by <i>Rhodotorula mucilaginosa</i> . <i>Infection</i> , 2003, 31, 181-183.	4.7	31
395	Gonococcal Tonsillar Infectionâ€‘A Case Report and Literature Review. <i>Infection</i> , 2003, 31, 362-365.	4.7	31
396	Glancing behind virus load variation in HIV-1 infection. <i>Trends in Microbiology</i> , 2003, 11, 499-504.	7.7	55

#	ARTICLE	IF	CITATIONS
397	HumanImmunodeficiency Virus Type 1 Fitness Is a Determining Factor in ViralRebound and Set Point in ChronicInfection. Journal of Virology, 2003, 77, 13146-13155.	3.4	54
398	Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4819-4824.	7.1	224
399	Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment Interruptions. Journal of Infectious Diseases, 2003, 188, 1433-1443.	4.0	121
400	HIV-1 p24 Antigen Is a Significant Inverse Correlate of CD4 T-Cell Change in Patients With Suppressed Viremia Under Long-Term Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 292-299.	2.1	41
401	A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. Aids, 2003, 17, 1487-1492.	2.2	21
402	HIV RNA in plasma rebounds within days during structured treatment interruptions. Aids, 2003, 17, 195-199.	2.2	82
403	A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 2003, 163, 1220.	3.8	153
404	Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antiviral Therapy, 2003, 8, 97-104.	1.0	13
405	Drug resistance mutations during structured treatment interruptions. Antiviral Therapy, 2003, 8, 411-5.	1.0	10
406	Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy, 2003, 8, 443-54.	1.0	8
407	Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection <i>in vivo</i> . Antiviral Therapy, 2003, 8, 97-104.	1.0	23
408	Drug Resistance Mutations during Structured Treatment Interruptions. Antiviral Therapy, 2003, 8, 411-415.	1.0	37
409	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. Antiviral Therapy, 2003, 8, 443-454.	1.0	23
410	Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load. Aids, 2002, 16, 2317-2322.	2.2	22
411	Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Do Not Predict Viral Growth and Clearance Rates during Structured Intermittent Antiretroviral Therapy. Journal of Virology, 2002, 76, 10169-10176.	3.4	43
412	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13747-13752.	7.1	199
413	A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2002, 185, 1251-1260.	4.0	132
414	Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. Journal of Clinical Immunology, 2002, 22, 363-374.	3.8	32

#	ARTICLE	IF	CITATIONS
415	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1967-1969.	2.2	107
416	Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. <i>Antiviral Therapy</i> , 2002, 7, 91-103.	1.0	36
417	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts. <i>Antiviral Therapy</i> , 2002, 7, 91-103.	1.0	62
418	Liver failure after long-term nucleoside antiretroviral therapy. <i>Lancet</i> , The, 2001, 358, 759-760.	13.7	12
419	Directex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8+ T lymphocyte activation in response to therapeutic manipulation of virus load. <i>European Journal of Immunology</i> , 2001, 31, 1115-1121.	2.9	28
420	Evidence for Positive Selection Driving the Evolution of HIV-1 env under Potent Antiviral Therapy. <i>Virology</i> , 2001, 284, 250-258.	2.4	42
421	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 397-404.	2.1	12
422	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 397-404.	2.1	46
423	Residual Human Immunodeficiency Virus (HIV) Type 1 RNA and DNA in Lymph Nodes and HIV RNA in Genital Secretions and in Cerebrospinal Fluid after Suppression of Viremia for 2 Years. <i>Journal of Infectious Diseases</i> , 2001, 183, 1318-1327.	4.0	146
424	Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 171.	7.4	312
425	Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. <i>Aids</i> , 2000, 14, 31-36.	2.2	160
426	Impact of TNF α , LT α , Fc γ RII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients. <i>Aids</i> , 2000, 14, 2661-2669.	2.2	5
427	Residual HIV-RNA Levels Persist for Up to 2.5 Years in Peripheral Blood Mononuclear Cells of Patients on Potent Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1135-1140.	1.1	52
428	Effect of Influenza Vaccination on Viral Replication and Immune Response in Persons Infected with Human Immunodeficiency Virus Receiving Potent Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2000, 181, 522-531.	4.0	120
429	Antiretroviral resistance during successful therapy of HIV type 1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 10948-10953.	7.1	205
430	Treatment-Induced Decline of Human Immunodeficiency Virus-1 p24 and HIV-1 RNA in Lymphoid Tissue of Patients with Early Human Immunodeficiency Virus-1 Infection. <i>American Journal of Pathology</i> , 2000, 156, 1973-1986.	3.8	34
431	Sequence Clusters in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Are Associated with Subsequent Virological Response to Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 1999, 180, 1043-1049.	4.0	16
432	Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 5169-5172.	7.1	70

#	ARTICLE	IF	CITATIONS
433	Higher Selection Pressure from Antiretroviral Drugs in Vivo Results in Increased Evolutionary Distance in HIV-1 pol. <i>Virology</i> , 1999, 259, 154-165.	2.4	32
434	Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1<i>pol</i> from Clinical Samples. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 869-876.	1.1	140
435	Spinal Osteomyelitis Caused by <i>Candida glabrata</i> . <i>Infectious Diseases in Clinical Practice</i> , 1998, 7, 112-116.	0.3	1
436	Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia. <i>Science</i> , 1997, 278, 1291-1295.	12.6	2,071
437	Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 12574-12579.	7.1	240
438	Analysis of Restriction Fragment Length Polymorphism and Ribotyping of Multiresistant <i>Stenotrophomonas maltophilia</i> Isolated from Persisting Lung Infection in a Cystic Fibrosis Patient. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 499-502.	1.5	17
439	Pharmacokinetics of an HIV-1 gp120-specific chimeric antibody in patients with HIV-1 disease. <i>Biotherapy</i> (Dordrecht, Netherlands), 1993, 6, 205-215.	0.7	5
440	Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPLâ€™™HIV Trial). <i>Frontiers in Virology</i> , 0, 2, .	1.4	0